Vera Therapeutics Inc, based in Brisbane, California, is a biotechnology firm dedicated to creating innovative treatments for severe immunological diseases. With a focus on research and development, its flagship product, atacicept, is a pioneering fusion protein aimed at treating immunoglobulin A nephropathy and lupus nephritis through subcutaneous injections in advanced clinical trials. Additionally, Vera is working on MAU868, a monoclonal antibody designed to combat BK viremia infections, showcasing its commitment to addressing unmet medical needs in immunology.
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
